LOW
42
14
BXP
39
5
FOX
71
3
MRK
25
2
ADP
57
2
SWK
53
4
AON
25
4
CME
59
3
HPE
48
2
MTCH
62
22
HIG
48
5
XYL
29
4
HAS
29
3
AIZ
61
5
CSCO
63
5
EIX
61
8
GOOGL
62
6
AMP
43
2
PLD
35
5
BIIB
36
8
LOW
42
14
BXP
39
5
FOX
71
3
MRK
25
2
ADP
57
2
SWK
53
4
AON
25
4
CME
59
3
HPE
48
2
MTCH
62
22
HIG
48
5
XYL
29
4
HAS
29
3
AIZ
61
5
CSCO
63
5
EIX
61
8
GOOGL
62
6
AMP
43
2
PLD
35
5
BIIB
36
8
Financhill
Back

The Vita Coco 10K Form

Buy
60

COCO
The Vita Coco

Last Price:
$35.85
Seasonality Move:
6.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive COCO News And Ratings

See the #1 stock for the next 7 days that we like better than COCO

COCO Financial Statistics

Sales & Book Value

Annual Sales: $493.6M
Cash Flow: $8.9M
Price / Cash Flow: 29.41
Annual Sales: $4.44
Price / Book: 8.07

Profitability

EPS (TTM): 0.99000
Net Income (TTM): $59.4M
Gross Margin: $180.7M
Return on Equity: 27.26%
Return on Assets: 19.53%

The Vita Coco Earnings Forecast

Key The Vita Coco Financial Ratios

  • The Gross Profit Margin over the past 15 years for COCO is 36.61%.
  • The Selling, General & Administrative Expenses for COCO have been equal to 25.17% of Gross Profit Margin.
  • The Research & Development expenses have been 0.00% of Revenue.
  • The Interest Expense is 0.07% of Operating Income.
  • The Net Earning history of COCO is 9.45% of Total Revenues.
  • Per Share Earnings over the last 15 years have been positive in 8 years.

The Vita Coco Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Beverages
Sector: Consumer Staples
Current Symbol: COCO
CUSIP: 218868
Website: thevitacococompany.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.28
Quick Ratio: 2.34

Price-to-Earnings

Trailing P/E Ratio: 45.42
Forward P/E Ratio: 31.02

COCO Technical Analysis vs Fundamental Analysis

Buy
60
The Vita Coco (COCO) is a Buy

Is The Vita Coco a Buy or a Sell?

  • The Vita Coco stock is rated a Buy
    The current The Vita Coco [COCO] share price is $35.88. The Score for COCO is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.